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Oat (Avena sativa) is a cereal known since antiquity as a useful grain with abundant nutritional and health benefits. It contains
distinct molecular components with high antioxidant activity, such as tocopherols, tocotrienols, and flavanoids. In addition, it is
a unique source of avenanthramides, phenolic amides containing anthranilic acid and hydroxycinnamic acid moieties, and
endowed with major beneficial health properties because of their antioxidant, anti-inflammatory, and antiproliferative effects. In
this review, we report on the biological activities of avenanthramides and their derivatives, including analogs produced in
recombinant yeast, with a major focus on the therapeutic potential of these secondary metabolites in the treatment of aging-
related human diseases. Moreover, we also present recent advances pointing to avenanthramides as interesting therapeutic
candidates for the treatment of cerebral cavernous malformation (CCM) disease, a major cerebrovascular disorder affecting up
to 0.5% of the human population. Finally, we highlight the potential of foodomics and redox proteomics approaches in
outlining distinctive molecular pathways and redox protein modifications associated with avenanthramide bioactivities in
promoting human health and contrasting the onset and progression of various pathologies.
The paper is dedicated to the memory of Adelia Frison
1. Introduction
Oats are cereal grain crops belonging to the family of Poaceae
(or Gramineae) [1]. Two main species of oat grow naturally,
namely, Avena sativa and Avena nuda. The former, known as
common oat, is the most widely cultivated, especially in
the cool and moist regions of Northern Europe and North
America [2]. Among the common cereal grains, oats are
consumed at lower rates than wheat and rice all over the
world. However, dietary fiber content, nutritional value,
and health benefits of oats are high. Indeed, the increasing
interest of consumers towards whole grain oats is mainly
driven by its advantageous composition in macronutrients:
(i) lipids with a high degree of unsaturation, including
oleic and linoleic acids (about 40% and 36% of total fatty
acids, resp.), (ii) proteins with a favorable composition of
essential amino acids, and (iii) dietary fibers with a high
content of β-glucan (2–8.5% w/w of oat seed). In particular,
the high levels of β-glucan present in oats have been shown
to contribute in reducing total plasma concentration of
cholesterol and low-density lipoprotein (LDL) cholesterol,
the main risk factors for coronary heart disease (CHD).
A growing body of evidence suggests that oats contain
other important bioactive compounds, such as phenolic
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compounds, which exert protective effects against the devel-
opment of various pathologies, including cardiovascular dis-
eases (CVDs), diabetes, inflammatory bowel disease (IBD),
cancer, obesity, and celiac disease, acting synergistically with
dietary fibers [3]. Phenolic compounds are major secondary
products of plant metabolism, consisting of at least one aro-
matic ring bearing one or more hydroxyl groups (phenolic
unit). Their chemical structure may range from that of a sim-
ple phenolic molecule (phenolic acids) to that of a complex
high molecular weight polymer (polyphenols). Depending
on the number and type of phenolic units, they can be
divided into at least 10 different molecular classes, including
simple phenols (phenolic acids), and intermediate (e.g., flavo-
noids and anthocyanins) and high (e.g., stilbenes, coumarins,
and tannins) molecular weight polyphenols. From the biolog-
ical point of view, phenolic compounds have been show to
possess numerous activities, the most important being the
antioxidant activity, which prevents lipid peroxidation and
cellular oxidative damage mediated by harmful free radicals
[4, 5]. This property is related to the ability of phenolic
compounds to scavenge free radicals, donate hydrogen
atoms or electron, or chelate metal cations, which is dic-
tated mainly by the number and position of the hydroxyl
groups and the nature of substitutions on the aromatic
rings, as demonstrated by structure-activity relationship
analyses. More in general, phenolic compounds have been
involved in cellular defense against various stressful events
[2, 6, 7] and shown to possess several health-promoting
properties [8], including prophylactic activity against arte-
riosclerosis, CVDs, inflammatory processes, and certain
forms of cancer [9, 10].
The type and concentration of phenolic compounds in
whole-grain cereals are influenced by the plant variety and
grain nature. In particular, besides containing high levels
of phenolic acids, tocopherols, and alk(en)ylresorcinol
derivatives, oats are a unique source of avenanthramides
(Avns; also known as N-cinnamoylanthranilate alkaloids
or anthranilic acid amides), which are not present in other
cereals [11]. Avns are low molecular weight phenolic
amides consisting of an anthranilic acid linked to a hydro-
xycinnamic acid with an amide bond (Figure 1). They
were originally identified as phytoalexins produced by
the plant in response to exposure to pathogens, such as
fungi [12, 13]. Oats contain a unique group of approxi-
mately 40 different types of Avns, which are present in
both oat grains and leaves [14–16]. The most abundant
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Figure 1: Chemical structure and names of some natural (Avn), synthetic (Tranilast), and recombinant (YAvn) avenanthramides. Avns are
low molecular weight phenolic compounds consisting of an anthranilic acid linked to a hydroxycinnamic acid with an amide bond. Different
forms of Avns have been either extracted from oats, produced by chemical synthesis, or generated by recombinant DNA techniques in
yeast cells.
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are Avn-A (N-(4′-hydroxycinnamoyl)-5-hydroxyanthrani-
lic acid), Avn-B (N-(4′-hydroxy-3′-methoxycinnamoyl)-5-
hydroxyanthranilic acid), and Avn-C (N-(3′-4′-dihydrox-
ycinnamoyl)-5-hydroxyanthranilic acid) (Figure 1), which
are amides of 5-hydroxyanthranilic acid with p-coumaric,
ferulic, and caffeic hydroxycinnamic acids, respectively
[13, 17, 18]. These Avns are constitutively expressed in
the kernel, reaching the highest concentration in the
bran, and appear in almost all milling fractions [17]. A
number of studies demonstrate that these natural products
have strong antioxidant activity both in vitro and in vivo, as
well as anti-inflammatory, anti-itching, anti-irritant, anti-
atherogenic, and antiproliferative activities, which may
prevent or limit cellular oxidative dysfunctions and the
development of oxidative stress-related diseases, such as
neurodegenerative and cardiovascular diseases, and provide
additional protection against skin irritation, aging, CHD,
and cancer [16, 17, 19–32].
Apart from natural compounds isolated from oats,
avenanthramide analogs endowed with important biological
properties have been artificially produced by organic
synthesis methodologies, including the pharmaceutical drug
Tranilast™ (N-[3′,4′-dimethoxycinnamoyl]-anthranilic acid;
Rizaban, Kissei Pharmaceutical Co., Japan), which is cur-
rently used in Japan and South Korea as an antihistamine
to treat bronchial asthma, atopic dermatitis, keloids and
hypertrophic scars, allergic conjunctivitis, allergic rhinitis,
and other allergic disorders [33–35]. Notably, whereas
several years of clinical use have established that Tranilast
has very low adverse effects and good toleration by
patients, the beneficial effects of this drug have also been
seen in a variety of other pathologies, such as sclero-
derma and other skin diseases related to excessive fibrosis,
cancer, diabetes, and autoimmune, cardiovascular, and
renal diseases [36]. Tranilast efficacy has been mainly
attributed to its capacity to inhibit the release of proin-
flammatory factors from leukocytes, including mast cells
and macrophages, and suppress collagen deposition, and
has been associated mainly with the inhibition of the
TGF-β pathway, although this drug affects other pathways
as well [37, 38].
Besides natural and synthetic Avns, novel Avn ana-
logs have been produced in recombinant yeast, including
N-(4′-hydroxycinnamoyl)-3-hydroxyanthranilic acid (YAvn
I) and N-(3′-4′-dihydroxycinnamoyl)-3-hydroxyanthranilic
acid (YAvn II), which were generated by engineering a
Saccharomyces cerevisiae strain with two plant genes (4cl-2
from tobacco and hct from globe artichoke) encoding key
proteins involved in the biosynthesis of phenolic esters [39].
Remarkably, YAvn I and YAvn II share structural similarity
with Avn-A and Avn-C, respectively (Figure 1), and were
shown to possess bioactive properties relevant to biomedical
applications, including potent antioxidant, anti-inflamma-
tory, and antiproliferative properties. Indeed, they were effec-
tive in rescuing major pathological phenotypes in both
cellular and animal models of Cerebral Cavernous Malfor-
mation (CCM) disease, a human cerebrovascular disorder
of genetic origin implicating oxidative stress and inflamma-
tion as main pathogenetic events [40, 41].
2. Radical-Scavenging and Antioxidant
Activity of Avenanthramides
The antioxidant activity of oat components was initially
suggested by the evidence that oat flour could be used
as a food preservative from oxidative deterioration due
to its ability in retarding the initial peroxide formation
and rancidity [42, 43]. Subsequently, Lingnert and
coworkers originally determined the antioxidative capacity
of N-(4′-hydroxy-3′-methoxy-(E)-cynnamoil)-5-hydroxyan-
thranilic acid and N-(4′-hydroxy-3′-methoxy-(E)-cynna-
moil)-5-hydroxy-4-methoxyanthranilic acid in oxygen
consumption experiments with a linoleic acid-based system
[44]. The antioxidant properties of oat extracts and their com-
ponents, including avenanthramides, were eventually demon-
strated directly by assaying purified compounds from different
oat cultivars [45, 46]. In particular, Emmons and colleagues
examined oat milling fractions to determine their potential
as dietary antioxidants, showing that three avenanthramide
isoforms (Avn-A, Avn-C, and Avn-K) were among the most
important oat metabolites endowed with antioxidant activity
[46]. Then, Peterson and coworkers synthesized the three
major oat avenanthramides (Avn-A, Avn-B, and Avn-C)
and tested their antioxidant activities using two in vitro assays,
such as the inhibition of beta-carotene bleaching and the reac-
tion with the free radical 2,2-diphenyl-1-picrylhy-drazyl
(DPPH), demonstrating that Avn-C has greater antioxidant
activity than Avn-B and Avn-A [47].
The antioxidant properties of Avns were also investigated
in in vivo models. In particular, Avn-C supplementation in
the diet of rats at a concentration of 0.1 g/kg was effective in
reducing reactive oxygen species (ROS) levels in the soleus
muscle. Moreover, Avn-C-fed rats had higher superoxide
dismutase activity in the vastus lateralis muscle (DVL), liver,
and kidney, and higher glutathione peroxidase activity in the
heart and DVL, compared to control rats. In addition, Avn-C
supplementation attenuated the increased ROS production
in the soleus and lipid peroxidation in the heart induced by
exercise [19].
The bioavailability of Avns was examined by Chen and
coworkers in hamsters [22], where it was observed that
plasma concentration of Avns and phenolic acids peak at
40min after the animals were gavage with saline containing
0.25 g oat bran phenol-rich powder. While p-coumaric acid
was the most bioavailable among oat phenolics, Avn bio-
availability appeared very low, probably due to metabolite
distribution in other tissues and the corresponding biotrans-
formation rate. The same authors also investigated the bio-
availability and antioxidant action of major Avns, including
Avn-A, Avn-B, and Avn-C, in humans [21]. At doses of 0.5
and 1.0 g of an Avn-enriched mixture (AEM), Avns reached
the maximum peak in plasma at 1.5 and 2.3 h, respectively.
Avn-A and Avn-B bioavailability was 18- and 5-fold higher
in humans than in hamsters, respectively. Interestingly,
consumption of Avn-enriched oat extracts significantly
increased the plasma concentration of reduced glutathione
(GSH), the body’s master antioxidant. Specifically, after
consumption of 0.1 g of AEM, plasma GSH levels increased
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21% from baseline at 15min, without apparent adverse side
effects [21]. Moreover, Avn-rich extract from oat was also
reported to possess an effective antioxidant activity against
D-galactose-induced oxidative stress [48]. Furthermore, it
was demonstrated that Avns, including Avn-A, significantly
increased heme oxygenase-1 (HO-1) expression in HK-2
cells in both dose- and time-dependent manners, showing
that this effect involved ROS production and Nrf2 nuclear
translocation [49, 50].
The Avn analog Tranilast was also reported to be
effective in reducing the generation of ROS, including
hydrogen peroxide (H2O2) and hydroxyl radical (OH
•),
suggesting potential clinical applications [51]. However,
the mechanisms of its antioxidant activity are yet to
be clarified.
On the other hand, Avn analogs produced in recom-
binant yeast, including YAvn I and YAvn II, were origi-
nally shown to have strong antioxidant activity when
tested in an ABTS•+ radical quenching assay, as well as
the capacity to reduce intracellular ROS levels in a cellu-
lar model of CCM disease, as evaluated with a cellular
antioxidant assay [39]. Subsequent in vitro studies dem-
onstrated that YAvn I and YAvn II positively regulate cell
antioxidant defense mechanisms through the upregulation
of forkhead box protein O1 (FOXO1) and superoxide
dismutase 2 (SOD2) expression levels [40]. In addition,
recent studies in an animal model of CCM disease have
extended these findings, demonstrating the effectiveness
of YAvns in major oxidative stress-related disease pheno-
types [41] (Table 1).
3. Anti-Inflammatory
Activity of Avenanthramides
The ancient literature already described the anti-
inflammatory and anti-itching properties of oat extracts. In
fact, Greek and Latin literatures report the use of oatmeal
as topical therapy for a variety of dermatological conditions
[29]. Since 1945, several studies showed the benefits of colloi-
dal oatmeal bath as soothing treatment as well as nonirritat-
ing, cleansing formulation for inflamed, itchy skin associated
with various xerotic dermatitis [16, 29]. Despite widespread
use for skin irritation, the phytochemicals present in oat
and responsible for the anti-inflammatory activity were not
defined until 2004. Liu and colleagues first reported the
potential anti-inflammatory and antiatherogenic properties
of Avn-enriched extracts of oats, which inhibited the IL-1β-
stimulated endothelial cell secretion of proinflammatory
cytokines (IL-6) and chemokines (IL-8 and MCP-1), as well
as expression of adhesion molecules (ICAM-1, VCAM-1,
and E-selectin) and adhesion of monocytes to endothelial cell
monolayer [29]. Similarly, CH3-Avn-C, a synthetically pre-
pared methyl ester derivative of Avn-C, significantly and
dose-dependently decreased mRNA expression and secretion
of IL-6, IL-8, and MCP-1 in endothelial cells and inhibited
IL-1β- and TNFα-stimulated NF-κB activation by preventing
the phosphorylation of IκB kinase and IκB [26]. Moreover,
Sur and colleagues found that keratinocites treated with Avns
displayed a significant inhibition of TNF-induced NF-κB
activity and subsequent reduction of IL-8 release, suggesting
that oat Avns may have putative anti-itching activity [16].
Table 1: Antioxidant activity of natural, synthetic, and recombinant avenanthramides.
Year Compound Effects Ref.
1937 Oat flour Food preservation from oxidative deterioration [42, 43]
1987 Tranilast
Reduction of intracellular levels of ROS, including hydrogen
peroxide (H2O2) and hydroxyl radical (OH
•)
[51]
2003 Avns
Antioxidant activity demonstrated by using DPPH (2,2-diphenyl-1-
picrylhydrazyl), FRAP (ferric reducing antioxidant potential),
and linoleic acid assays
[20, 24, 28]
2003 Avn-C
Upregulation of superoxide dismutase and glutathione peroxidase
activities and attenuation of exercise-induced ROS production and
lipid peroxidation in the heart and skeletal muscles of rats
[19]
2004
Supplementation of Avn-enriched
extract of oats
Interaction with vitamin C to enhance hamster and human
LDL resistance to oxidation
[22]
2007
Consumption of Avn-enriched extract
of oats
Antioxidant activity in humans: increase of the plasma-reduced
glutathione level after consumption
[21]
2010 Avn-rich extract from oat Effective against D-galactose-induced oxidative stress [48]
2010 YAvns
Reduction of intracellular ROS levels in a cellular model of
CCM disease
[39]
2015 YAvns
Upregulation of FOXO1 and SOD2 expressions in a cellular
model of CCM disease
[40]
2015 Avns
Upregulation of heme oxygenase-1 (HO-1) expression in both a
dose- and time-dependent manner mediated by Nrf2 translocation
[50]
2017 YAvns Antioxidant effects in a mouse model of CCM disease [41]
2018 Natural and synthetic Avns Antioxidant effects on CaCo-2 and Hep3B cancer cells [83]
Avns: avenanthramides; FOXO1: forkhead box protein O1; ROS: reactive oxygen species; SOD2: superoxide dismutase 2; YAvns: yeast avenanthramides.
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Furthermore, dihydro-avenanthramide D (DH Avn-D), a
synthetic analog of avenanthramide, was shown to inhibit
mast cell degranulation and exhibit anti-inflammatory effects
through the activation of the neurokinin-1 receptor [52]. In
addition, avenanthramide supplementation was able to
attenuate exercise-induced inflammation in postmenopausal
women by reducing neutrophil respiratory burst activity,
plasma C-reactive protein and IL-1β levels, and NF-κB
activation in peripheral blood mononuclear cells [53]. Nota-
bly, differences in the ability to inhibit NF-κB among Avns
have been ascribed to molecular structural variations [54].
On the other hand, the anti-inflammatory properties of
the Avn analog Tranilast have been attributed mainly to its
capacity to inhibit the release of chemical mediators from
mast cells and basophils [34, 55], suppress COX-2 and iNOS
expression [56], and limit TNFα-induced secretion of IL-6
and surface expression of vascular adhesion molecules,
including VCAM-1, ICAM-1 and E-selectin, in endothelial
cells by inhibiting NF-κB-dependent gene transcription
[38]. Furthermore, Tranilast anti-inflammatory properties
were shown to be triggered by the induction of HO-1 expres-
sion via ERK1/2 activation [55]. Finally, recombinant YAvns
were demonstrated to downregulate NF-κB and rescue
inflammatory phenotypes in cellular and animal models of
CCM disease [41] (Table 2).
4. Antiproliferative
Activity of Avenanthramides
Clear evidence demonstrates that Avns, including Avn-C and
its methylated derivative (CH3-Avn-C), can significantly
inhibit proliferation of distinct cell lines, such as human
colon and breast cancer cells, and vascular smooth muscle
cells (VSMC) [25, 31, 57]. Indeed, it has been reported that
Avns induce cell cycle arrest at the G1 phase by upregulating
the p53-p21cip1 pathway and inhibiting phosphorylation of
the retinoblastoma protein (pRB) [25], and may activate apo-
ptosis [57]. Moreover, methylated Avn-C was shown to
inhibit proteasome activity and increase the levels of
ubiquitin-conjugated proteins in endothelial cells, suggesting
that inhibition of proteasome activity and consequent stabili-
zation of the p53 protein are a plausible mechanism underly-
ing the inhibitory effect of Avns on the cell cycle [25]. In
particular, by testing the antiproliferative effect of Avns on
distinct cancer cell lines, it was found that Avn-enriched
oat extracts, Avn-C, and the methyl-ester derivative of Avn-
C were more effective on colon cancer cell lines, including
CaCo-2, HT29, LS174T, and HCT116 cells, than on prostate
or breast cancer cell lines [25]. Furthermore, the synthetic
DH Avn-D was shown to inhibit human breast cancer cell
invasion through inhibition of MAPK/NF-κB and MAPK/
AP-1 pathways and suppression of MMP-9 expression [32].
In addition, the Avn analog Tranilast was shown to exert
inhibitory effects on proliferation, epithelial-mesenchymal
transition (EMT), and invasion of cancer cells [58]. More-
over, it was reported to inhibit proliferation, chemotaxis,
and tube formation of human microvascular endothelial cells
in vitro and angiogenesis in vivo [59], as well as vascular
endothelial growth factor (VEGF)-induced vascular per-
meability [60], suggesting that it might ameliorate
angiogenesis-related diseases, such as tumor metaplasia,
rheumatoid arthritis, diabetic retinopathy, and age-related
Table 2: Anti-inflammatory activity of natural, synthetic, and recombinant avenanthramides.
Year Compound Effects Ref.
1997 Tranilast Inhibition of COX-2 and iNOS expression [56]
2002 Tranilast Inhibition of cytokine-induced NF-κB activation [16]
2004 Avn-enriched extract of oats
Inhibition of IL-6, IL-8, and MCP-1 secretion and ICAM-1, VCAM-1,
and E-selectin expression
[29]
2008 CH3-Avn-C
Reduction of mRNA expression and secretion of IL-6, IL-8, andMCP-1
and inhibition of IL-1β- and TNFα-stimulated NF-κB activation in
endothelial cells
[26]
2008 Avns
Inhibition of TNF-induced NF-κB activity and reduction of IL-8
release keratinocites. Putative anti-itching activity
[29]
2008 Avns
Inhibition of tumor necrosis factor alpha (TNF-alpha) induced NF-κB
luciferase activity and subsequent reduction of interleukin-8 (IL-8)
[16]
2014 Avn-based diet supplementation Attenuation of exercise-induced inflammation [53]
2015 Avn-enriched oat bran
Modulation of specific biomarkers of inflammation in older,
overweight, or obese adults
[82]
2017 YAvns
Inhibition of NF-κB and rescue of inflammatory phenotypes in cellular
and mouse models of CCM disease
[41]
2017 DH Avn-D
Interaction with the neurokinin-1 receptor (NK1R), inhibition of mast
cell degranulation, and reduction of the secretion of the cytokine
interleukin-6 (IL-6)
[52]
2018 Natural and synthetic Avns Anti-inflammatory effects on CaCo-2 and Hep3B cancer cells [83]
Avns: avenanthramides; CCM: cerebral cavernous malformation; CH3-Avn-C: methyl ester of Avn-C; COX-2: cyclooxygenase-2; DH Avn-D: dihydro-
avenanthramide D; ICAM-1: intercellular adhesion molecule 1; iNOS: inducible nitric oxide synthase; MCP-1: monocytic chemotactic protein-1; NF-κB:
nuclear factor kappa-light-chain-enhancer of activated B cells; TNFα: tumor necrosis factor alpha; VCAM-1: vascular cell adhesion molecule 1; YAvns:
yeast avenanthramides.
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macular degeneration, acting as a novel angiogenesis inhibi-
tor [59, 61, 62]. Finally, recent evidence demonstrates that
recombinant YAvn I and YAvn II are endowed with stronger
antiproliferative properties than natural Avns, including
Avn-B, due to their enhanced capacity of reducing intracellu-
lar ROS levels and cyclin D1 expression [40] (Table 3).
5. Therapeutic Benefits of Avenanthramides
There is compelling evidence that oxidative stress plays a
major role in the pathogenesis and progression of major
human diseases, including atherosclerosis, diabetes,
inflammatory diseases, cardiovascular diseases, cancer, and
neurological disorders, such as amyotrophic lateral sclerosis,
Alzheimer’s (AD) and Parkinson’s (PD) diseases [63], and is
also implicated in aging [64].
Oxidative stress occurs either when excess ROS are
produced in cells, which could overwhelm the normal
antioxidant capacity, or upon impairment of antioxidant
defense mechanisms. ROS toxicity contributes to protein,
lipid and DNA damage, inflammation, cell and tissue injury,
and apoptosis. Nevertheless, ROS also play important physi-
ological functions, whereas emerging evidence demonstrates
that the biological impact of ROS depends not only on
their intracellular levels and rate of formation and decay
but also on their chemical nature and subcellular localization
[65, 66]. Thus, inappropriate removal of ROS by antioxidants
may cause paradoxical reductive stress and thereby induce or
promote disease [63, 67, 68].
Due to their capacity to scavenge ROS and prevent
oxidative stress, antioxidants (including natural and syn-
thetic phenolic compounds) have long been credited with
helping to live longer and stay healthier, and looked upon
as effective therapeutic options for prevention and treatment
of various oxidative stress-related diseases. Natural antioxi-
dants are primarily phenolics that may occur in all parts of
Table 3: Antiproliferative activity of natural, synthetic, and recombinant avenanthramides.
Year Compound Effects Ref.
1994–1996 Tranilast
Blockage of PDGF-induced cell-cycle progression at the G1/S
checkpoint, inhibition of VSMC proliferation, and suppression
of intimal hyperplasia after photochemically induced endothelial injury
in the rat
[31]
1994–1997 Tranilast
Proposed as a putative therapeutic agent for prevention and treatment
of diseases associated with neovascularization, such as diabetic
retinopathy, senile discoid macular degeneration, neovascular
glaucoma, and rheumatoid arthritis
[59–62]
2001 Tranilast
Inhibition of migration and invasiveness of human malignant
glioma cells
[37]
2002 Tranilast
Inhibition of pancreatic cancer cell proliferation and
tumor angiogenesis
[58]
2003 Tranilast Inhibition of oral squamous cell carcinoma growth and invasion [76]
2006 Avn-C and CH3-Avn-C Inhibition of VSMC proliferation [31]
2006 Avn-C
Inhibition of SMC proliferation by upregulating the p53-p21cip1
pathway and inhibiting pRB phosphorylation
[30, 31]
2009 Tranilast Inhibition of human prostate adenocarcinoma cell proliferation [74]
2009 Tranilast Inhibition of neurofibroma cell growth [81]
2010 Tranilast
Effectiveness in the treatment of desmoid tumor of the chest
wall and inhibition of breast cancer stem cells
[73]
2010 Tranilast
Inhibition of murine and human breast cancer cell
proliferation and migration
[79, 80]
2010
Avn-enriched extracts of oats,
Avn-C, and CH3-Avn-C
Antiproliferative effects on distinct colon cancer cell lines [25]
2011 DH Avn-D
Inhibition of human breast cancer cell invasion through
downregulation of MAPK/NF-κB and MAPK/AP-1 pathways and
suppression of MMP-9 expression
[32]
2015 YAvns
Stronger antiproliferative properties than natural Avns, including
Avn-B, due to enhanced capacity of reducing intracellular ROS levels
and cyclin D1 expression
[40]
2017 Avns
Antiproliferative effect on breast cancer cells through an antiapoptotic
mechanism as revealed by annexin V and caspase activities
[57]
2018 Natural and synthetic Avns
Cytotoxic and proapoptotic effects on CaCo-2 and
Hep3B cancer cells
[83]
Avns: avenanthramides; CH3-Avn-C: methyl ester of Avn-C; DH Avn-D: dihydro-avenanthramide D; PDGF: platelet-derived growth factor; ROS: reactive
oxygen species; VSMC: vascular smooth muscle cells; YAvns: yeast avenanthramides.
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plants [69]. Specifically, beneficial effects on human health of
phenolic compounds with high antioxidant properties
obtained from oats have been reported in many studies and
shown to protect cells against oxidative damage [23, 70].
Furthermore, several compositions containing oat Avns or
derivatives have been described in pharmaceutical patents
for use in cosmetic, nutraceutical, and therapeutic prepa-
rations due to their antioxidant, anti-inflammatory, anti-
itching, antiallergic, antihistaminic, antiasthmatic, and anti-
aging activities. In particular, the synthetic drug Tranilast has
been approved since 1982 in Japan and South Korea and, as
mentioned above, is currently used as an antihistamine to
treat bronchial asthma, atopic dermatitis, allergic conjuncti-
vitis, allergic rhinitis, and other allergic disorders, with indi-
cations for keloids and hypertrophic scars, scleroderma,
and other skin disease related to excessive fibrosis [36]. In
addition, it was proposed for treatment of autoimmune dis-
eases, such as arthritis and multiple sclerosis, and as an inhib-
itor of angiogenesis [37, 71]. Moreover, the high potential of
Tranilast in inhibiting pathological cellular growth processes,
such as tumor-related ones, was investigated with promising
results [37, 58, 72–81].
On the other hand, a randomized, placebo-controlled,
double-blind pilot study, led to determine whether the
Avn-enriched bran reduces biomarkers of inflammation,
demonstrated that consuming Avns in a whole food form,
that is, Avn-enriched oat bran, may affect specific bio-
markers of inflammation in older, overweight, or obese
adults [82]. Considering the anti-inflammatory properties
of Avns and their capacity to inhibit smooth muscle cell
proliferation and increase NO production, these com-
pounds were proposed for prevention or therapy of ath-
erosclerosis and associated cardiovascular diseases. Data
also pointed to the potential benefit of including oats
and oat bran in daily meals over the long term [26]. Inter-
estingly, recent evidence highlighted the combined antiox-
idant, anti-inflammatory, and anticancer effects of
individual synthetized Avns and a mixture of natural Avns
on CaCo-2 and Hep3B cancer cells, showing that both
natural and synthetic Avns activate caspases 2, 8, and 3
and downregulate hTERT, MDR1, and COX-2 genes,
and suggesting that oat-based foods fortified with Avns
could be an alternative to produce functional foods with
major health benefits [83]. Furthermore and importantly,
recent findings demonstrated that both Tranilast and
YAvns were effective in rescuing prooxidant and proin-
flammatory phenotypes associated with CCM disease, a
cerebrovascular disorder associated with altered redox
homeostasis and signaling and enhanced susceptibility to
oxidative stress and inflammatory insults, thus widening
the therapeutic potential of these compounds [41].
6. Avenanthramides as Potential
Therapeutics for Cerebral Cavernous
Malformation Disease
CCM, also known as cavernous angioma or cavernoma, is a
major cerebrovascular disease characterized by clusters of
abnormally dilated and leaky capillaries occurring in brain,
spinal cord, and retina, with a prevalence of 0.3–0.5% in the
general population. These vascular anomalies, referred to as
CCM lesions, can be single or multiple (up to hundreds), as
detected by magnetic resonance imaging, and may result in
severe clinical symptoms at any age, including recurrent
headaches, focal neurological deficits, seizures, stroke, and
intracerebral hemorrhage (ICH) [84]. CCM disease has
proven genetic origin (OMIM 116860), being caused by
loss-of-function mutations in three genes, KRIT1 (CCM1),
CCM2, and PDCD10 (CCM3). It may arise sporadically or
is inherited as autosomal dominant condition with incom-
plete penetrance and highly variable expressivity even among
members of the same family, including wide differences in
lesion number, size, and susceptibility to ICH [84–86].
Despite significant recent advances in our understanding of
the pathophysiology of CCM disease, no direct therapeutic
approaches are available so far, besides the surgical removal
of accessible lesions [84, 87].
Accumulated evidence demonstrates that loss-of-
function mutations of CCM genes have pleiotropic effects
on several redox-sensitive molecules and mechanisms that
control cellular homeostasis and defenses against oxidative
stress and inflammation, thereby sensitizing cells to local
oxidative stress and inflammatory events [84, 86, 88–95]. In
particular, KRIT1 loss-of-function has been shown to affect
major antioxidant pathways and mechanisms, including
the FOXO1-SOD2 axis and the Nrf2 antioxidant pathway
[89, 94], and the autophagic degradation of dysfunctional,
ROS-generating mitochondria [89, 91]. On the other hand,
there is emerging evidence that Avns, including YAvns,
can enhance cellular defenses against oxidative stress by
inhibiting the activity of prooxidant and proinflammatory
proteins, such as NADPH oxidase and NF-κB [41], and stim-
ulating the upregulation of antioxidant molecules, such as
GSH and SOD2 [21, 40]. Indeed, treatment of KRIT1-
knockout and KRIT1-silenced cellular models with YAvns
was effective in reverting molecular phenotypes caused by
KRIT1 loss-of-function, including the downregulation of
FOXO1 and SOD2 and the upregulation of cyclin D1 [40].
Furthermore, both YAvns and Tranilast were able to induce
a rescue of major phenotypic signatures in a mouse model
of CCM disease, including altered redox homeostasis and sig-
naling, destabilized endothelial cell-cell junctions and blood-
brain barrier, enhanced vascular permeability, and reduced
susceptibility to oxidative stress and inflammatory insults,
suggesting potential therapeutic benefits for CCM disease
[41]. Further studies aimed at a comprehensive characteriza-
tion of the pleiotropic effects and mechanisms of action of
natural and recombinant Avns will provide useful insights
into these and other promising therapeutic benefits.
7. Avenanthramide and Aging Processes: A New
Elixir of Youth?
Oatmeal has been used for centuries as a soothing agent to
relieve itch and irritation associated with various xerotic
dermatoses. Today, it is available in various dosage forms
from powders for the bath to shampoos, shaving gels, and
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moisturizing creams, and has been approved as a skin protec-
tant by the US Food and Drug Administration (FDA) [27].
Among oat constituents, Avns are known to suppress
histamine release at very low doses, helping to plump up
the skin, reduce wrinkles, and restore the skin natural
barrier. Indeed, oat Avns have been shown to represent the
main group of active polyphenolic antioxidants responsible
for oatmeal anti-inflammatory, antierythema (antiredness),
antipruritic (anti-itching), and antihistaminic properties.
Consistently, several studies have demonstrated their
benefits in reducing eczema and other inflammatory skin
conditions [16]. Another health and antiaging benefit of
oat Avns is their antigenotoxic activity, which can protect
the DNA of epidermal cells against environmental insults,
including UV irradiation [21]. In hair care, oat Avns have
been shown to prevent lipid peroxidation in human hair fol-
licles and alleviate scalp itchiness and tenderness, indicating
Avns as an ideal active ingredient for scalp care formulations
[25]. Furthermore, Avns have been shown to prevent oxida-
tion of LDL cholesterol and inhibit the first stages of athero-
sclerosis, gaining the reputation of being able to protect the
aging cardiovascular system. In addition, as also described
in this review, several studies in the past few years have sug-
gested that oat Avns may be beneficial in the treatment of
various aging-related human diseases associated with chronic
oxidative stress and inflammation [96]. Notably, Avns exert
their strong antioxidant and anti-inflammatory properties
even at very low doses.
Taken together, the established beneficial effects of
Avns in skin protection and treatment of dermatological
diseases, and their emerging potentiality to prevent and
treat chronic oxidative stress and inflammation associated
with onset, progression and severity of aging-related dis-
eases, including metabolic, cardiovascular, cerebrovascular
and neurodegenerative diseases, point to these compounds
as promising new elixir of youth with both cosmetic and
pharmaceutical applications.
8. Foodomics for Elucidating Molecular
Pathways Underlying Biological Effects of
Avenanthramides in Chronic Diseases
Nutrition research has traditionally explored the functional
importance of diverse food categories through a careful
evaluation of various physiological phenomena and molecu-
lar markers characterizing a group of individuals fed with a
defined diet. Bioactive food constituents may have signifi-
cant beneficial effects for health promotion and disease
prevention, with various compounds active in reducing the
sustained oxidative stress and inflammation accompanying
chronic diseases, for example, CVDs and/or metabolic syn-
dromes. Unfortunately, chronic disorders are often complex,
multifactorial pathogenetic processes; they are the result of
combined genomic variant peculiarities interacting with
environmental/behavioral factors. Hence, not only genetic
factors but also homeostatic alterations related to the
environment may be crucial in disease onset, progression,
and severity.
In the last few years, nutrition research has moved from
classical physiology and epidemiology to chemical biology,
molecular biology, and genetics [97]. It has evolved similarly
to pharmacological research, where the topic effect of a
specific drug is evaluated on a defined cellular/organism
model subjected to controlled perturbative events (such as
drug treatment at a specific concentration and for a defined
time), which are then assayed according to a holistic per-
spective through combined molecular approaches [98, 99].
In this context, foodomics has emerged as a novel and multi-
disciplinary research field in nutrition science, which aims at
elucidating how diet can influence organism health [100,
101]. It is well known that bioactive compounds present in
foods, when assimilated, can affect gene expression profiles
in organism tissues/organs, and corresponding protein levels
and metabolite representations, thus contributing to modu-
lating the incidence of several chronic diseases. The study
of these complex interactions requires the integration of
different analytical approaches generating various dataset,
which then are interpreted according to a system biology
perspective by dedicated bioinformatic methods [102]. Thus,
in a foodomics experiment, (i) genomics takes advantage of
DNA microarray technologies to detect mRNA expression
changes in response to diet; (ii) proteomics uses quantitative
LC and MS methods combined with isotopic labelling
procedures (TMT, iTRAQ, or SILAC) to define protein
profile variations in dietary interventions; (iii) metabolomics
uses the same separation and measure techniques to define
the bioavailability of bioactive molecules in food and their
molecular changes after ingestion, as well as organism
plasma/urine metabolite profiles in response to diet; (iv)
genetics defines common genetic variants involved in the
individual response to diet through whole genome sequenc-
ing techniques. Integration of all information according to a
multiomic elaboration allows simultaneously deciphering
gene expression pathways, protein levels, and metabolite
concentrations that are affected in healthy individuals
experiencing a certain diet; the same information can be
obtained for subjects suffering a certain pathological condi-
tion. Thus, it is possible to formulate dietary recommenda-
tions based on a system biology perspective to ensure a
healthy condition or to prevent and treat chronic diseases,
such as CVDs, obesity, and cancer [103]. In this context, we
particularly underline the importance of foodomics studies
that over time have been performed on human, animals,
and animal models of human diseases administered with
(i) rosemary extracts rich in polyphenols [104–106] and
corresponding isolated metabolite carnosol and carnosic acid
[107, 108]; (ii) red-to-blue fruit extracts rich in anthocyanins
[109]; (iii) vegetable extracts rich in flavonoids [110] and
isoflavones or isolated genistein, daidzein [111], and flavone
[112]; (iv) green tea extracts rich in polyphenols [113]; (v)
olive oil extracts rich in polyphenols [114]; (vi) fish oil
extracts rich in polyunsaturated fatty acids [115]; (vii)
resveratrol-containing foods [116]; (viii) inulin-containing
prebiotics and isolated inulin; (ix) increased dietary pro-
tein [117, 118]; (x) nutrients lacking normal Zn supplement
[119]; (xi) augmented folate [120] and multivitamin/mineral
supplement [121]. Due to the complexity of these studies,
8 Oxidative Medicine and Cellular Longevity
their results were often published in different articles. In most
cases, experiments were performed on individuals fed with a
food matrix containing various bioactive compounds; this is
similar to other “omic” investigations, where traditional
pharmacological remedies were tested through holistic
approaches [122–124]. In the next future, it is desirable that
advanced foodomics studies, analogous to those reported
above for other foods, will also be performed on organisms
or animal models of human diseases fed with oat com-
pounds, including isolated Avns and their recombinant
derivatives, to unveil the molecular mechanisms underlying
the corresponding biological effects and therapeutic benefits
reported above. To this regard, particular attention should
be paid to the effects of Avns on the intestinal microbiome,
as this has been recognized as a fundamental player in
human health and disease, affecting a variety of conditions
such as host energy balance and immune responses [125],
and has been recently implicated also in the pathogenesis of
CCM disease, suggesting that manipulation of the bacterial
microbiome may indeed be an effective therapeutic approach
[126]. It is therefore important that future foodomics investi-
gations will also include information from gut-residing bac-
teria and consequent modulation of the gut-brain axis.
9. Redox Proteomics for Detailing Chemical
Modifications Hampered by
Avenanthramides in Chronic Diseases
Oxidative and nitrosative stresses, due to an imbalance
between the generation of ROS and reactive nitrogen species
(RNS), and the antioxidant defense capacity of the organism,
are important pathophysiological events contributing to the
onset and progression of several human pathologies, includ-
ing cardiovascular diseases and metabolic syndromes [127,
128]. ROS include superoxide anion (O2
•−), hydroxyl
(OH•) and peroxyl (RO2
•), and alkoxyl (RO•) radicals, as well
as nonradical compounds, such as hydrogen peroxide
(H2O2), hypochlorous acid (HOCl) and organic peroxides,
which can be produced from either endogenous (e.g., mito-
chondrial electron transport chain, cytochrome P450 mono-
oxygenases, and NADPH oxidases) or exogenous sources
(e.g., pollutants, drugs, xenobiotics, and radiation). On the
other hand, RNS are reactive compounds derived from nitric
oxide (NO•) following the activity of inducible nitric oxide
synthases, and include peroxynitrite (ONOO−), alkyl perox-
ynitrite (ROONO), nitrogen dioxide (NO2
•), and other
molecules [129].
ROS and RNS affect major cellular components, includ-
ing lipids, DNA and proteins, modifying their structure. In
particular, hundreds of adducts of distinct nature have been
identified in proteins as a result of the reaction of ROS and
RNS with chemical groups present in amino acid side chain
[130]. Through modulation of protein structure/function,
ROS and RNS can influence a number of enzymatic activities
and protein functions, thus affecting intracellular signal
transduction pathways and gene expression profiles. While
several enzymatic and nonenzymatic markers of chronic oxi-
dative and nitrosative stresses are well known in different
organs and body tissues/fluids, early protein targets of oxida-
tive and nitrosative injuries are now becoming to be defined.
The identification of putative oxidative biomarkers takes
advantage of redox proteomics [131], which is indeed a
branch of proteomics specifically designed to identify oxi-
dized and nitrosized proteins and determine nature, extent,
and location of oxidative/nitrosative posttranslational modi-
fications in the proteomes of interest. Gel-based and gel-free
redox proteomics techniques often use liquid chromatogra-
phy coupled to mass spectrometry as the major platform to
achieve the goal of identifying and fully characterizing
oxidized and nitrosized target proteomes. In this context,
dedicated redox proteomics methods have been developed
to quali-quantitatively investigate (i) Cys oxidation to
sulfenic, sulfinic, and sulfonic acid; (ii) Cys conversion to
intra- and intermolecular cystine derivatives; (iii) Cys
conversion into S-nitrosyl-cysteine; (iv) Met sulfoxidation
to sulfone/sulfoxide derivatives; (v) Trp oxidation and
nitrosation to (di)hydroxytryptophan, N-formylkynurenine,
hydroxykynurenine, kynurenine, and nitrotryptophan; (vi)
His oxidation to oxindolylalanine, 2-oxo-histidine, and 5-
hydroxy-2-oxo-histidine; (vii) Tyr oxidation, nitrosation,
and halogenation to di- and tri-hydroxyphenylalanine,
3,3′-dityrosine, 3-nitrotyrosine, and 3,(5)-(di)halotyrosine,
respectively; (viii) Pro, Arg, Lys, and Thr direct oxidation
to 2-pyrrolidone, glutamic acid semialdehyde, aminoadipic
semialdehyde, and 2-amino-3-ketobutyric acid, respec-
tively; (ix) Lys and Arg glyco-oxidation to generate more
than fifty distinct derivatives; (x) Cys, His, and Lys reac-
tions with α,β-unsaturated aldehydes deriving from lipid
peroxidation to generate more than thirty distinct deriva-
tives; (xi) Cys modification with electrophic prostaglandins
and isoprostanes deriving from arachidonic acid oxida-
tion. Once identified, oxidized and nitrosized proteins
can be placed in specific molecular pathways to provide
insights into affected molecular and cellular functions
associated with human diseases.
Conventional and early detection of above-mentioned
oxidized and nitrosized protein markers in various diseases
and metabolic syndromes has thus enabled to hypothesize a
relationship between pathological hallmarks of such disor-
ders and protein structural/functional modifications. This is
the case of distinctive identifications of (i) carbonylation,
Tyr chlorination, and Met sulfoxidation of target proteins
in plasma and atherosclerotic lesions from subjects affected
by coronary artery diseases [132, 133]; (ii) glycated, carbony-
lated, Met-sulfoxidized, Tyr-nitrated, and S-nitrosylated pro-
teins in biological fluids and tissues of diabetic patients, or
tissues of related animal models [134–144]; (iii) carbonyla-
tion, Tyr nitration, and S-glutathionylation of target proteins
in brain tissues of AD and mild cognitive impairment
patients, or animal models of AD, PD, HD, and ALS [145–
150]; (iv) oxidized, carbonylated, and Tyr-nitrated and chlo-
rinated proteins in body tissues of patients and animal
models experiencing various acute inflammatory syndromes
[151, 152]; (v) carbonylated proteins in bronchoalveolar
lavage of patients with sarcoidosis and pulmonary fibrosis
[153]; (vi) carbonylated proteins in the diaphragm and mus-
cle tissues of severe chronic obstructive pulmonary disease
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patients and related animal models [154, 155]; (vii) gly-
coxidized and carbonylated proteins in urine and the kidney
of patients with dialysis-related amyloidosis [156–158]; (viii)
oxidized proteins in human liver tissues after ischemia/
reperfusion [159]; (ix) redox modified proteins in various
tissues as a result of aging [160–168]; (x) carbonylated,
Tyr-nitrated, and S-sulphenylated proteins in hypertensive
kidney disease [169–171]; (xi) oxidized proteins in the amni-
otic fluid of preeclamptic women [172]. Whenever inserted
in perturbative experiment pipelines, redox proteomics
approaches are now allowing a monitoring of the degree of
corresponding body tissue damage and the response to
pharmacological therapies.
At the same time, they will provide a rationale to the pos-
itive/negative effects of a diet on healthy individuals and/or
on patients suffering pathological conditions. In this context,
pioneering experiments have been performed to evaluate the
impact of (i) excessive caloric intake on oxidized and carbo-
nylated proteins from adipose tissues of healthy men [173];
(ii) fasting on Cys-oxidized proteins from healthy ani-
mals [174]; (iii) high-fat and high-sucrose diet on carbo-
nylated proteins from tissues and body fluids of healthy
animals [175]; (iv) the assumption of glutathione derivatives
on Tyr-nitrated proteins from brain-injured animal models
[176]; (v) antioxidant-fortified diet on carbonylated and
Tyr-nitrated proteins from brain tissues of animal models
of AD [177]; (vi) high-fat and alcohol diet on carbony-
lated and Cys-oxidized proteins from tissues and body
fluids of fatty liver disease patients and related animal
models [178–184]. In the close future, it is hypothesized
that redox proteomics studies will also be performed on
organisms or animal models of human diseases fed with
oat compounds and derivatives, including isolated natural
and recombinant Avns, in order to evaluate the capacity
of such nutraceuticals to modulate oxidized and nitrosized
proteomes in target tissues and body fluids.
10. Concluding Remarks
It is generally accepted that antioxidants exert health-
promoting effects by scavenging intracellular ROS; thus, their
consumption as food additives and nutraceuticals has been
greatly encouraged. Nonetheless, to date, there is little clinical
evidence for the long-term benefits of most antioxidants,
while there are even alarms of health risks consequent to
supplementation of lipophilic antioxidants [68]. Accord-
ingly, the existence of a physiological role of specific ROS
concentrations can explain the negative results from clinical
trials, where large doses of exogenously-administered antiox-
idants or hyperactivation of antioxidant pathways with elec-
trophilic therapeutics failed to improve outcomes of
oxidative stress-related diseases or resulted even deleterious
[63, 67, 185, 186]. Indeed, it is now well established that
redox reactions bear the Janus faceted feature of promoting
both physiological signaling responses and pathological cues
in all biological systems, as well as that endogenous antioxi-
dant molecules and mechanisms participate in both scenar-
ios [63, 67]. Consistently, emerging evidence demonstrates
that only intermediate levels of major regulators of antioxi-
dant responses are beneficial, although both the low and high
concentration thresholds for physiological versus pathologi-
cal effects may vary largely depending on genetic and envi-
ronmental factors and the cellular context [185]. Thus,
given that most of the emerging therapeutic compounds with
antioxidant properties influence redox-sensitive mecha-
nisms, both their low and high concentration thresholds for
physiological versus pathological effects have to be carefully
considered.
In this light, further studies are necessary to fully address
the beneficial effects of Avns in human health, including anti-
oxidant, antiproliferative, anti-inflammatory, antiaging, and
anticancer activities (Figure 2). In particular, useful insights
could be derived from foodomics and redox proteomics
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Figure 2: Bioactivities and potential health benefits of avenanthramides. Both natural, synthetic, and recombinant avenanthramides have
been shown to exhibit strong antioxidant, anti-inflammatory, and antiproliferative activities, which may provide protection against various
cellular dysfunctions and human pathologies, including aging-related diseases.
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studies aimed at a comprehensive characterization of mol-
ecules and mechanisms that mediate the pleiotropic effects
of Avns in cellular and animal models of human diseases,
including oxidative posttranslational modifications of
structural and regulatory proteins. Moreover, novel
therapeutic approaches, including combinatorial therapy
and nanotechnology-based targeted drug delivery, are
encouraged in order to allow site-directed application,
appropriate dosing regimens, pharmacological repair of
oxidized biomolecules, and triggering of endogenous anti-
oxidant response systems, which could also be guided by
the identification of predictive biomarkers.
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